N-[(2Z)-1,3-benzothiazol-2(3H)-ylidene]-2-(1H-indol-3-yl)acetamide | 775310-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[(2Z)-1,3-benzothiazol-2(3H)-ylidene]-2-(1H-indol-3-yl)acetamide
• 英文别名: N-(1,3-benzothiazol-2-yl)-2-(1H-indol-3-yl)acetamide
• CAS: 775310-67-3
• 化学式: C₁₇H₁₃N₃OS
• 分子量: 307.376
• InChiKey: BJZUVKVWKVGPDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  86
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[(2Z)-1,3-benzothiazol-2(3H)-ylidene]-2-(1H-indol-3-yl)acetamide 、 碘甲烷 在 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以51 %的产率得到N-(benzo[d]thiazol-2-yl)-N-methyl-2-(1-methyl-1H-indol-3-yl)acetamide
  参考文献：
  名称：

  신규 화합물 및 이의 건선, 천식 또는 전신홍반루푸스의 치료 용도

  摘要：

  本发明涉及用于治疗银屑病、哮喘或全身性红斑狼疮的新化合物及其制备物，包含本发明新化合物的药学组合物不仅可以控制炎症，还可以平衡免疫系统并修复受损组织以恢复组织稳态，具有优异的银屑病、哮喘或全身性红斑狼疮的治疗和预防效果。

  公开号：

  KR20220137555A
• 作为产物：
  描述：

  2-氨基苯并噻唑 、 3-吲哚乙酸 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以6 %的产率得到N-[(2Z)-1,3-benzothiazol-2(3H)-ylidene]-2-(1H-indol-3-yl)acetamide
  参考文献：
  名称：

  신규 화합물 및 이의 건선, 천식 또는 전신홍반루푸스의 치료 용도

  摘要：

  本发明涉及用于治疗银屑病、哮喘或全身性红斑狼疮的新化合物及其制备物，包含本发明新化合物的药学组合物不仅可以控制炎症，还可以平衡免疫系统并修复受损组织以恢复组织稳态，具有优异的银屑病、哮喘或全身性红斑狼疮的治疗和预防效果。

  公开号：

  KR20220137555A

文献信息

• 신규 화합물 및 이의 건선, 천식 또는 전신홍반루푸스의 치료 용도
  申请人：Parenchyma Biotech Inc. 파렌키마바이오텍 주식회사(120200691320) Corp. No ▼ 180111-1176361BRN ▼284-81-01208

  公开号：KR20220137555A

  公开（公告）日：2022-10-12

  본 발명은 신규 화합물 및 이의 건선, 천식 또는 전신홍반루푸스의 치료 용도에 관한 것으로서, 본 발명의 신규 화합물을 포함하는 약학 조성물은 염증 제어뿐 아니라 면역 밸런스 및 손상 조직을 복구하여 조직 항상성을 회복시킬 수 있으며 건선, 천식 또는 전신홍반루푸스 치료 및 예방 효과가 우수하다

  本发明涉及用于治疗银屑病、哮喘或全身性红斑狼疮的新化合物及其制备物，包含本发明新化合物的药学组合物不仅可以控制炎症，还可以平衡免疫系统并修复受损组织以恢复组织稳态，具有优异的银屑病、哮喘或全身性红斑狼疮的治疗和预防效果。
• Pyrazine derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0511879A1

  公开（公告）日：1992-11-04

  Novel pyrazine derivatives have the formula (1) in which: wherein R is a hydrogen atom or a lower alkyl group;    Rl is a lower alkoxy group, a lower alkyl group or a hydroxy group;    R³ is a lower alkyl group, a phenyl group, a phenyl- lower alkyl group, a lower alkenyl group or an indolyl-lower alkyl group;    R² is a phenyl-lower alkyl group which may have, on the phenyl ring, l to 3 substituents selected from the group consisting of a lower alkoxy group, a phenyl-lower alkoxy group, a lower alkyl group and a hydroxy group; a group of the formula wherein R⁴ and R ⁵ have the meanings given in the description. Processes for preparing the pyrazine derivatives are also described. These compounds can be used in pharmaceutical compositions for inhibiting the activities of superoxide radical (O₂⁻) and for preventing and treating nephritis.

  新型吡嗪衍生物具有式（1），其中 其中 R 是氢原子或低级烷基； Rl 是低级烷氧基、低级烷基或羟基； R³ 是低级烷基、苯基、苯基-低级烷基、低级烯基或吲哚基-低级烷基； R²是苯基低级烷基，在苯基环上可有 l 至 3 个取代基，这些取代基可从低级烷氧基、苯基低级烷氧基、低级烷基和羟基组成的组中选出； 式中的一个基团 其中 R⁴和 R ⁵ 具有说明中给出的含义。此外，还介绍了吡嗪衍生物的制备工艺。这些化合物可用于药物组合物中，以抑制超氧自由基（O₂-）的活性，预防和治疗肾炎。
• Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy
  作者：Christopher R. Gardner、Belamy B. Cheung、Jessica Koach、David StC. Black、Glenn M. Marshall、Naresh Kumar

  DOI：10.1016/j.bmc.2012.09.035

  日期：2012.12

  Indole-3-amides and dipeptides were produced from 2-aminobenzothiazoles using the PyBop peptide coupling reagent. These analogues were tested in anti-cancer cell viability assays against SH-SY5Y neuroblastoma and MDA-MB-231 breast adenocarcinoma cell lines, and were found to exhibit cytotoxic activities at concentrations ranging from 0.1 to 20 mu M. These compounds were also found to act additively with a low dosage of 13-cis-retinoic acid in neuroblastoma cells. Then, using neuroblastoma cells transfected to stably overexpress the RAR beta(2) gene, a SAR was developed for the indole-3-amides. Real-time PCR was also used to demonstrate their RAR beta(2) agonistic activity. (C) 2012 Elsevier Ltd. All rights reserved.
• COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES
  申请人：PARENCHYMA BIOTECH INC.

  公开号：US20230020507A1

  公开（公告）日：2023-01-19

  A compound according to an embodiment is represented by Formula 1. The compound may be used for treatment of autoimmune diseases. A composition for treatment or prevention of autoimmune diseases includes the compound and is expected to not only control inflammation but also recover immune balance as well as damaged tissues, thereby restoring bowel tissue homeostasis.